Skip to content

Safety and efficacy of endovascular treatment in acute distal arterial occlusive stroke: a multicenter, prospective registration study

Safety and efficacy of endovascular treatment in acute distal arterial occlusive stroke: a multicenter, prospective registration study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076903
Enrollment
Unknown
Registered
2023-10-24
Start date
2023-10-30
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) age =18 years old; 2) stroke onset within 24 hours; 3) an NIHSS score > 5 or a disabling NIHSS score between 3 and 5 at the time of presentation (e.g., strabismus, aphasia, loss of hand function), as determined by the treating physician according to the patient's living conditions; 4) Distal vessel occlusion stroke confirmed by CTA/MRA (MCA: Distal M2, M3, M4; ACA: A1, A2, A3; PCA: P1, P2, P3) and were responsible for the signs and symptoms of acute ischemic stroke. 5) the patient or family signed written informed consent.

Exclusion criteria

Exclusion criteria: 1) intracranial hemorrhage confirmed by imaging; 2) mRS Score =2 before onset; 3) pregnant or lactating women; 4) known allergies to iodine, heparin, anesthesia, or other clear contraindications to endovascular therapy (EVT); 5) The presence of seizures at stroke onset or before treatment and inaccurate NIHSS baseline score; 6) systolic blood pressure > 220mmHg or diastolic blood pressure > 120mmHg, which could not be controlled with antihypertensive drugs; 7) genetic or acquired bleeding constitution, anticoagulant factor deficiency; Or had oral anticoagulants and INR> 3. 8) Blood glucose 22.2mmol/L (400mg/dl), platelet 220µmol/L (2.5mg/dl)); 10) suspected aortic dissection, 11) life expectancy due to advanced stage of any disease < 6 months; 12) anticipated inability to complete follow-up; 13) brain tumors with mass effect (except small meningiomas) or a significant mass effect with midline shift on imaging; 14) are participating in other clinical research; 15) Other circumstances that the investigator believes would pose a significant risk to the subject if they participated in the study.

Design outcomes

Primary

MeasureTime frame
The rate of 90-day modified RANKIN scale (mRS) score 0-1 (%);mortality at 90 days;Incidence of symptomatic intracranial hemorrhage within 48 hours;

Secondary

MeasureTime frame
Shift in the distribution of mRS scores at 90 days;Proportion of patients with functional independence (mRS score 0 to 2) at 90 days;

Countries

China

Contacts

Public ContactYangmei Chen

The Second Affiliated Hospital of Chongqing Medical University

chenym1997@sina.com+86 136 0834 8562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026